Bright Minds Biosciences Inc. (DRUG)
DRUGNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$23.11
+0.3700 (+1.63%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $226.93m
- P/E
- –
- EPS, last 4 quarters
- $-2.08
- Dividend yield
- –
- Day range
- –
- 52-week range
- $17.40 to $123.75
- Average volume
- –
- Previous close
- $22.74
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $134.17, +480.6% from here
Earnings
next estimate $-1.07Next report Dec 22, 2026
Sep 2025
+41.4%
Dec 2025
+28.6%
Mar 2026
+31.6%
Jun 2026
+87.8%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split RTTNews · Nov 6, 2026
- FDA Places Bright Minds' Planned Phase 2 BMB-101 Study On Partial Clinical Hold; Stock Plunges RTTNews · Nov 2, 2026
- What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?Zacks · Aug 27, 2026
- Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?Zacks · Aug 26, 2026
- Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a BetZacks · Aug 10, 2026
- Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?Zacks · Jul 23, 2026
- All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong BuyZacks · Jul 22, 2026
- Why a $5 Million New Position Signals Confidence in This Epilepsy Drug PipelineThe Motley Fool · May 21, 2026
The company
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- brightmindsbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.